CoChat

Safety and tolerability of high doses of taspoglutide, a once‐weekly human GLP‐1 analogue, in diabetic patients treated with metformin: a randomized double‐blind placebo‐controlled study 1,2

Open access
Ratner, R., Nauck, M., Kapitza, C., Asnaghi, V., Boldrin, M., Balena, R. · 2010 · Diabetic Medicine
Cited by 44

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Diabet. Med. 27, 556–562 (2010) Aims The study objective was to investigate the safety and tolerability of up‐titration to high doses of taspoglutide, a once‐weekly human glucagon‐like peptide‐1 analogue, in subjects with Type 2 diabetes inadequately controlled on metformin alone. Methods In this double‐blind phase II trial, subjects were randomized to placebo or taspoglutide (20 mg; three separate groups) administered once weekly by subcutaneous injection for 4 weeks. This was followed by dose maintenance at 20 mg, or titration to 30 mg (20/30) or 40 mg (20/40) once weekly with matched placebo for an additional 4 weeks. Subjects were monitored for adverse events (AEs) throughout the study and 4‐week follow‐up. Results One hundred and twenty‐nine subjects were randomized and treated [mean age 57 years, mean baseline glycated haemoglobin (HbA 1c ), 7.9%]. The most frequently reported AEs were nausea and vomiting. The number of patients reporting gastrointestinal AEs did not increase following titration to higher doses of taspoglutide or when continuing the initial 20 mg regimen. Three subjects were withdrawn from the study as a result of gastrointestinal AEs (one before and two after titration to higher doses). Although not designed to investigate efficacy, improvement in glycaemic control was observed in all active arms of the study. The proportion of subjects achieving HbA 1c < 7.0% after 8 weeks of treatment was 72, 53 and 70% in the 20/20‐, 20/30‐ and 20/40‐mg arms, respectively, vs. 19% for placebo. Conclusions Taspoglutide was safe, well tolerated at high doses and efficacious for lowering HbA 1c . Up‐titration of dose was not associated with a worsening AE profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2010.02990.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 44

Metadata

Authors
Ratner, R., Nauck, M., Kapitza, C., Asnaghi, V., Boldrin, M., & Balena, R.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2010-04-21
Volume
27
Issue
5
Pages
556-562
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2155617439
Cited by
44
References
3
FWCI
6.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and tolerability of high doses of taspoglutide, a once‐weekly human GLP‐1 analogue, in diabetic patients treated with metformin: a randomized double‐blind placebo‐controlled study 1,2. https://app.cochat.ai/papers/10.1111/j.1464-5491.2010.02990.x
The paper
Ratner, R., Nauck, M., Kapitza, C., Asnaghi, V., Boldrin, M., & Balena, R. (2010). Safety and tolerability of high doses of taspoglutide, a once‐weekly human GLP‐1 analogue, in diabetic patients treated with metformin: a randomized double‐blind placebo‐controlled study 1,2. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2010.02990.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.